TAR-0520 Gel

DRUG4 trials

Sponsors

Tarian Pharma

Conditions

Capecitabine-induced hand and foot syndromeEGFR inhibitor-induced folliculitisHand and Foot SyndromeTaxanes-induced peripheral neuropathy

Phase 2

A phase 2a multicentric study of TAR-0520 gel in EGFR inhibitor-induced folliculitis

RecruitingCTIS2024-516339-28-00

Tarian PharmaEGFR inhibitor-induced folliculitis

Start: 2025-02-10Target: 60Updated: 2025-08-29

A phase 2a Safety and Efficacy study of TAR-0520 gel in prevention of taxanes-induced peripheral neuropathy

RecruitingCTIS2025-521674-33-00

Tarian PharmaTaxanes-induced peripheral neuropathy

Start: 2025-11-05Target: 30Updated: 2025-06-27

A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome

Not yet recruitingCTIS2025-524008-32-00

Tarian PharmaCapecitabine-induced hand and foot syndrome

Target: 25Updated: 2026-02-16

TAR-0520 Gel in Hand and Foot Syndrome

Not yet recruitingNCT07457671

Tarian PharmaHand and Foot Syndrome

Start: 2026-03-01End: 2027-06-01Target: 25Updated: 2026-03-09